ASTRAZENECA PHARMA INDIA LTD. - 506820 - Authorised Key Managerial Personnel To Determine Materiality Of Events/Information
Authorised Key Managerial Personnel to determine materiality of events/information24-08-2022
24-08-2022
AstraZeneca may not stay in vaccines, but CEO has no COVID regrets
AstraZeneca may not stay in the vaccine business in the long run showing how quickly fortunes have changed for the drug-maker that produced one of the first COVID-19 shots but has since lost out to rivals23-08-2022
DCGI approves use of AstraZeneca's drug for patients with high-risk early breast cancer
The drug, Lynparza, will be used as monotherapy for the adjuvant treatment of adult patients20-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Drugs Controller General Of India For Olaparib 100Mg/150Mg Film Coated Tablets For Additional Indication
This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication. Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. The receipt of this permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza(r)) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.19-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Appointment Of Independent Director At The Annual General Meeting
In continuation of our earlier announcement dated December 30, 2021, we wish to inform you that at the Company's Annual General Meeting held on August 8, 2022, the Shareholders have approved the appointment of Ms. Shilpa Shridhar Divekar, as an Independent Director for a term of 5 years with effect from December 29, 2021 till December 28, 2026. The requisite details of the appointment pursuant to Regulation 30 of the Listing Regulations read with SEBI Circular dated September 9, 2015, are given as Annexure A.10-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
AstraZeneca Pharma India Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here10-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Clause 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish the attached details regarding voting results of 43rd Annual General Meeting of the Company held on Monday, August 8, 2022 at 3.00 pm through Video Conferencing/ Other Audio Visual Means along with the scrutinizer's report.10-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Outcome of AGM
We would like to inform you that the attached business were transacted at the 43rd Annual General Meeting (AGM) of the Company held on August 8, 2022 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means. Kindly note that voting results will be announced upon the receipt of Scrutinizer's Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.09-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Appointment of Company Secretary and Compliance Officer
With reference to the captioned subject, we wish to inform you that Mr. Pratap Rudra, Company Secretary has resigned as Company Secretary and Compliance Officer of the Company with effect from close of working hours of August 10, 2022. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company. Further, the Board has appointed Ms. Manasa. R as the Company Secretary and Compliance Officer of the Company w.e.f. August 11, 2022.08-08-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
With reference to the captioned subject, we wish to inform you that Mr. Pratap Rudra, Company Secretary has resigned as Company Secretary and Compliance Officer of the Company with effect from close of working hours of August 10, 2022. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company.08-08-2022